title: Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation.
abstract: Selective cyclooxygenase-2 (COX-2) inhibitors are widely used due to their efficacy and good safety profile. However, recent case reports have described varying degrees of liver injuries associated with the use of COX-2 inhibitors. We report the case of a patient who developed acute cholestatic hepatitis progressing to hepatic failure requiring liver transplantation, following a 3-d course of celecoxib for treatment of generalized muscle aches and pains. The clinical presentation, the laboratory data, as well as the liver histopathology were supportive of the putative diagnosis of drug induced liver injury.
authors.affiliation: Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
authors.forename: Ihab I
authors.initials: II
authors.lastname: El Hajj
authors.forename: Shahid M
authors.initials: SM
authors.lastname: Malik
authors.forename: Hany R
authors.initials: HR
authors.lastname: Alwakeel
authors.forename: Obaid S
authors.initials: OS
authors.lastname: Shaikh
authors.forename: Eizaburo
authors.initials: E
authors.lastname: Sasatomi
authors.forename: Hossam M
authors.initials: HM
authors.lastname: Kandil
mesh_terms: D000068579:Celecoxib; D002779:Cholestasis / Q000139:chemically induced*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017093:Liver Failure / Q000139:chemically induced / Q000601:surgery; D016031:Liver Transplantation; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib
references.citation: Hepatology. 1997 Sep;26(3):664-9
references.pmid: 9303497
references.citation: Ann Pharmacother. 2002 Dec;36(12):1887-9
references.pmid: 12452750
references.citation: J Clin Epidemiol. 1993 Nov;46(11):1323-30
references.pmid: 8229110
references.citation: Postgrad Med J. 2001 Aug;77(910):548-50
references.pmid: 11470953
references.citation: Eur J Gastroenterol Hepatol. 2007 Nov;19(11):919-22
references.pmid: 18049158
references.citation: J Hepatol. 2000 Jan;32(1):174
references.pmid: 10673086
references.citation: Crit Rev Toxicol. 1995;25(3):207-35
references.pmid: 7576152
references.citation: Expert Opin Pharmacother. 2007 Aug;8(11):1719-32
references.pmid: 17685888
references.citation: Ann Intern Med. 2001 Feb 6;134(3):254
references.pmid: 11177350
references.citation: BMJ. 2001 Jul 7;323(7303):23
references.pmid: 11440939
references.citation: Lancet. 1999 Jan 2;353(9146):40-1
references.pmid: 10023957
references.citation: N Engl J Med. 1991 Jun 13;324(24):1716-25
references.pmid: 2034249
references.citation: Ann Intern Med. 2002 Jul 2;137(1):75
references.pmid: 12093262
references.citation: Swiss Med Wkly. 2004 Apr 3;134(13-14):201
references.pmid: 15106034
references.citation: Dig Dis Sci. 2004 Mar;49(3):459-61
references.pmid: 15139498